CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution

Yang,Ling-Lin; Wang,Bi-Qiong; Chen,Lan-Lan; Luo,Hui-Qun; Wu,Jing-Bo

doi:10.3892/ol.2011.472

CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution

Authors:
- Ling-Lin Yang
- Bi-Qiong Wang
- Lan-Lan Chen
- Hui-Qun Luo
- Jing-Bo Wu
View Affiliations

Affiliations: Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China
Published online on: November 4, 2011 https://doi.org/10.3892/ol.2011.472
Pages: 383-386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiotherapy is a crucial treatment for cervical cancer, the second most common type of cancer in women worldwide. In this study, we investigated the effects of CXC chemokine ligand 10 (CXCL10) gene therapy combined with radiotherapy on cervical cancer using HeLa cells. TUNEL assay revealed that the apoptotic rate in the combined treatment of CXCL10 gene therapy and radiotherapy was greatly increased compared with that of CXCL10 or radiotherapy alone. Flow cytometry showed that CXCL10 overexpression in HeLa cells resulted in a prolonged G1 phase and shortened S phase at 72 h post-transfection. Western blot analysis revealed that p27Kip1 was up-regulated in CXCL10-treated HeLa cells; however, cyclin E was down-regulated. These results indicate that the combination of CXCL10 gene therapy and radiotherapy is an effective strategy for the growth suppression of HeLa cells, and that CXCL10 enhances the radiotherapy effects through cell cycle redistribution. Our data provide new insight into the treatment of cervical carcinoma, involving an effective combination of gene therapy and radiotherapy against tumors.

View Figures

View References

1	Schiffman M and Castle PE: The promise of global cervical-cancer prevention. N Engl J Med. 353:2101–2104. 2005. View Article : Google Scholar : PubMed/NCBI
2	Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J and Shah K: Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 287:2372–2381. 2002. View Article : Google Scholar : PubMed/NCBI
3	Moody CA and Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 10:550–560. 2010. View Article : Google Scholar : PubMed/NCBI
4	Schiffman M and Solomon D: Screening and prevention methods for cervical cancer. JAMA. 302:1809–1810. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sørbye SW, Fismen S, Gutteberg T and Mortensen ES: Triage of women with minor cervical lesions: data suggesting a ‘test and treat’ approach for HPV E6/E7 mRNA testing. PLoS One. 5:e127242010.PubMed/NCBI
6	Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K and Mundt AJ: Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 71:428–434. 2008.
7	Grigsby PW: Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer. Radiat Med. 23:327–330. 2005.PubMed/NCBI
8	Klopp AH and Eifel PJ: Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep. 13:77–85. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tanderup K, Georg D, Pötter R, Kirisits C, Grau C and Lindegaard JC: Adaptive management of cervical cancer radiotherapy. Semin Radiat Oncol. 20:121–129. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bromley SK, Mempel TR and Luster AD: Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol. 9:970–980. 2008. View Article : Google Scholar : PubMed/NCBI
11	Sallusto F and Baggiolini M: Chemokines and leukocyte traffic. Nat Immunol. 9:949–952. 2008. View Article : Google Scholar
12	Campanella GS, Colvin RA and Luster AD: CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One. 5:e127002010. View Article : Google Scholar : PubMed/NCBI
13	Liu M, Guo S and Stiles JK: The emerging role of CXCL10 in cancer. Oncol Lett. 2:583–589. 2011.PubMed/NCBI
14	Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE and Luster AD: IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 168:3195–3204. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP and Ben-Baruch A: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 67:3396–3405. 2007. View Article : Google Scholar : PubMed/NCBI
16	Zhang HM, Yuan J, Cheung P, Chau D, Wong BW, McManus BM and Yang D: Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression. Mol Cell Biol. 25:6247–6258. 2005. View Article : Google Scholar : PubMed/NCBI
17	Frosina G: DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res. 7:989–999. 2009. View Article : Google Scholar : PubMed/NCBI
18	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
19	Mazumder S, Plesca D and Almasan A: A jekyll and hyde role of cyclin E in the genotoxic stress response: switching from cell cycle control to apoptosis regulation. Cell Cycle. 6:1437–1442. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kawauchi S, Yamamoto Y, Uchida K, Chochi Y, Kondo T, Oga A and Sasaki K: Significance of cyclin E and p27 expression in malignant ovarian germ cell tumors: correlation with the cell proliferation activity and clinicopathologic features. Oncol Rep. 16:1029–1033. 2006.PubMed/NCBI
21	Bhatia B, Malik A, Fernandez A and Kenney AM: p27(Kip1), a double-edged sword in Shh-mediated medulloblastoma: Tumor accelerator and suppressor. Cell Cycle. 9:4307–4314. 2010. View Article : Google Scholar : PubMed/NCBI